In veterinary practices across the country, veterinary technicians and assistants handle hazardous pharmaceuticals every single day. From splitting methimazole tablets for hyperthyroid cats and counting chlorambucil for lymphoma patients, to reconstituting vincristine, administering doxorubicin, or applying transdermal hormone gels, occupational exposure is a daily reality.

Yet when practice owners, hospital administrators, and medical directors attempt to establish clear, compliant safety protocols, they frequently run into a confusing thicket of regulatory acronyms: NIOSH, USP Chapter 800, and OSHA.

Rumors and vendor marketing materials circulate claims that "USP 800 is a federal law that mandates a $100,000 cleanroom in every general practice," while other clinics operate under the dangerous assumption that "human drug rules do not apply to veterinarians at all."

Both extremes are incorrect.

With the publication of the 2024 NIOSH List of Hazardous Drugs in Healthcare Settings (published in the Federal Register in December 2024), the regulatory framework governing hazardous pharmaceuticals underwent its most significant structural update in a decade.

Below is an operational, compliance-first guide for veterinary practice managers, medical directors, and safety coordinators: untangling which standards are legally enforceable versus advisory, why splitting or crushing a single tablet triggers federal OSHA mandates, the extralabel reality revealed by FDA drug approval data, and an actionable four-step protocol for Monday morning.

Fast answer: What is legally enforceable in a veterinary clinic?

To cut through the regulatory confusion, understand how the three major frameworks interact with a US veterinary practice:

• 1. The NIOSH List is ADVISORY, not a regulation. In the December 20, 2024 Federal Register notice (89 FR 104163–104182), the National Institute for Occupational Safety and Health stated unequivocally: "The List is informational in nature and confers no requirements or legal obligations on users." NIOSH identifies which chemical entities pose carcinogenic, teratogenic, reproductive, or organ-toxicity hazards, but NIOSH has zero statutory enforcement authority.
• 2. USP General Chapter 800 is a COMPENDIAL STANDARD, not a federal law. Published by the United States Pharmacopeia (official December 1, 2019; compendially applicable November 1, 2023), Chapter 800 sets engineering and handling benchmarks for hazardous drugs. USP does not inspect or enforce its standards. Chapter 800 becomes legally binding on a veterinary clinic only if adopted into state law by your State Board of Pharmacy or State Veterinary Medical Board, or mandated by hospital accreditation (such as AAHA standards).
• 3. OSHA is the ENFORCEABLE FEDERAL REGULATOR. The Occupational Safety and Health Administration (OSHA) directly inspects and penalizes veterinary employers. While OSHA has no single standalone "hazardous drug rule," it enforces hazardous drug safety through:
  • The Hazard Communication Standard (HCS) (29 CFR 1910.1200).
  • The Personal Protective Equipment (PPE) Standard (29 CFR 1910.132).
  • The General Duty Clause (Section 5(a)(1) of the OSH Act), which requires employers to provide a workplace free from recognized hazards causing or likely to cause death or serious physical harm.
• 4. The Crushed-Tablet Exemption Reversal: Under OSHA standard interpretations, intact commercial pills and tablets are exempt from Hazard Communication labeling and Safety Data Sheet (SDS) requirements for administration. However, under OSHA's official May 11, 1993 veterinary standard interpretation: "if however, the solid pill or tablet is pulverized or crushed to facilitate administration then it is covered by the HCS." The moment a technician cuts, splits, or crushes a hazardous tablet, full OSHA compliance is triggered.

                  The Hazardous Drug Regulatory Triangle
┌────────────────────────────────────────────────────────────────────────────┐
│ 1. NIOSH (Scientific Identification)                                      │
│    • Publication: 2024 NIOSH List of Hazardous Drugs in Healthcare Settings│
│    • Legal Status: ADVISORY ONLY (Confers no direct legal obligations)     │
│    • Role: Classifies chemical hazards into Table 1 & Table 2              │
└─────────────────────────────────────┬──────────────────────────────────────┘
                                      │ Informs & Guides
┌─────────────────────────────────────▼──────────────────────────────────────┐
│ 2. USP GENERAL CHAPTER 800 (Compendial Practice Standard)                  │
│    • Publication: USP General Chapter 800 (Applicable Nov 1, 2023)         │
│    • Legal Status: COMPENDIAL (Enforced via State Boards & Accreditation)  │
│    • Role: Defines containment, ventilation, and handling procedures       │
└─────────────────────────────────────┬──────────────────────────────────────┘
                                      │ Referenced as Industry Standard
┌─────────────────────────────────────▼──────────────────────────────────────┐
│ 3. OSHA (Federal Enforceable Law)                                          │
│    • Standards: 29 CFR 1910.1200 (HazCom), 1910.132 (PPE), General Duty    │
│    • Legal Status: DIRECTLY ENFORCEABLE (Carries fines & citations)        │
│    • Role: Mandates written plans, SDS access, training, and exposure PPE  │
└────────────────────────────────────────────────────────────────────────────┘

---

Untangling the three acronyms: NIOSH vs. USP 800 vs. OSHA

Veterinary practice managers frequently treat NIOSH, USP, and OSHA as a single regulatory entity. Separating their legal jurisdictions clarifies your clinic's compliance obligations:

Comparison of Hazardous Drug Regulatory Frameworks
──────────────────────────────────────────────────────────────────────────
Framework          Agency Type          Enforcement Mechanism     Veterinary Impact
──────────────────────────────────────────────────────────────────────────
NIOSH List         Federal Research     None. Advisory scientific Informs your clinic's
(2024 List)        Agency (CDC)         hazard identification     Hazard Assessment &
                                        and screening resource    chemical inventory

USP General        Non-Governmental     State Boards of Pharmacy, Voluntary unless
Chapter 800        Standards-Setting    State Veterinary Boards,  adopted by state rule
                   Organization         AAHA Accreditation        or board inspection

OSHA Standards     Federal Regulatory   Federal/State OSHA        MANDATORY. Written
(29 CFR 1910)      Enforcement Agency   inspections, workplace    HazCom plan, PPE, SDS,
                                        citations, civil fines    training, waste rules
──────────────────────────────────────────────────────────────────────────

1. NIOSH: The scientific benchmark

The National Institute for Occupational Safety and Health (NIOSH), operating under the CDC, evaluates pharmaceutical toxicity data. A drug is placed on the NIOSH List if it exhibits one or more of six hazard criteria in humans or animal models:

• Carcinogenicity.
• Teratogenicity or other developmental toxicity.
• Reproductive toxicity.
• Organ toxicity at low doses.
• Genotoxicity.
• Structure and toxicity profiles of new drugs that mimic existing hazardous drugs.

In response to public comments on the 2024 update, NIOSH clarified that its mission is purely scientific: facilities must evaluate their own operational handling scenarios and implement risk management strategies proportional to actual exposure potential.

2. USP Chapter 800: The pharmacy and handling standard

USP General Chapter 800 ("Hazardous Drugs—Handling in Healthcare Settings") was developed to protect healthcare personnel, patients, and the environment during the receipt, storage, compounding, dispensing, administration, and disposal of hazardous drugs.

While Chapter 800 became compendially applicable on November 1, 2023, USP itself possesses no inspection or enforcement police. Its reach into a veterinary hospital depends entirely on whether:

• Your State Board of Veterinary Medical Examiners or State Board of Pharmacy has explicitly codified USP 800 into state administrative code.
• Your practice is accredited by the American Animal Hospital Association (AAHA), which incorporates hazardous drug safe-handling expectations into its oncology evaluation standards.

3. OSHA: The legal hammer

OSHA is the federal agency with direct, unannounced inspection authority over private veterinary practices. When an OSHA compliance officer inspects a clinic, they do not cite "USP 800 violations." Instead, they issue citations and monetary penalties under:

• 29 CFR 1910.1200 (Hazard Communication): Failure to maintain a written HazCom program, accessible Safety Data Sheets (SDSs), container warning labels, and documented employee training.
• 29 CFR 1910.132 (Personal Protective Equipment): Failure to conduct a workplace hazard assessment and provide appropriate, certified PPE (such as ASTM D6978 chemotherapy gloves) at no cost to employees.
• Section 5(a)(1) (General Duty Clause): Failure to protect employees from recognized occupational health hazards where feasible control measures exist. In General Duty citations, OSHA frequently references NIOSH and USP guidelines as evidence of recognized industry standards.

---

The 1993 OSHA veterinary standard interpretation: Why crushing or splitting a tablet changes everything

The single most consequential legal document for veterinary hazardous drug compliance is an official OSHA Standard Interpretation issued on May 11, 1993, addressing hazardous substances in veterinary practices.

Under the federal Hazard Communication Standard (29 CFR 1910.1200(b)(6)(vii)), drugs in solid final form (such as tablets or capsules) intended for direct administration to a patient are exempt from labeling and Safety Data Sheet requirements.

However, OSHA's veterinary interpretation establishes a critical dividing line:

*"The exemption at 1910.1200(b)(6)(vii) applies when a drug is in solid final form for direct administration to the patient. If however, the solid pill or tablet is pulverized or crushed to facilitate administration then it is covered by the HCS."*

                    The Solid Dosage Exemption Boundary
┌────────────────────────────────────────────────────────────────────────────┐
│ INTACT TABLET (Exempt from HazCom)     CRUSHED / SPLIT TABLET (Covered!)   │
│                                                                            │
│      ┌─────────┐                            ┌───┐   ┌───┐                  │
│      │  TABLET │                            │   │ + │   │  +  [AIRBORNE   ]│
│      └─────────┘                            └───┘   └───┘     [PARTICULATES]│
│                                                                            │
│ • Film coating intact                  • Fractured core releases powder    │
│ • No aerosolized dust generated        • Inhalation & dermal exposure risk │
│ • Standard prescription vial handling  • Requires HazCom Plan, SDS, PPE,   │
│ • Exempt from 29 CFR 1910.1200         • Mandates dedicated containment    │
└────────────────────────────────────────────────────────────────────────────┘

Why this matters in daily veterinary workflow

In companion animal practice, veterinary patients rarely match standard human adult tablet sizes. Technicians routinely split tablets using pill splitters or crush tablets to mix into food or liquid suspensions for cats and small dogs:

• Methimazole (Felimazole / Tapazole): Routinely prescribed for feline hyperthyroidism, and one of the most frequently split tablets in small-animal practice. When a technician cuts a methimazole tablet in half on an open treatment counter, chemical dust is generated.
• Chlorambucil (Leukeran): An alkylating antineoplastic agent (IARC Group 1 human carcinogen) used for feline small-cell lymphoma and canine immune-mediated disease. Cutting or splitting chlorambucil generates mutagenic particulates.
• Cyclophosphamide (Cytoxan): Splitting tablets creates direct cytotoxic aerosol contamination.

Under OSHA law, the moment your team cuts, splits, crushes, or compounds a hazardous medication, the solid dosage exemption evaporates. Your practice must have a written hazard assessment, an active Safety Data Sheet on file, documented staff training, and mandatory personal protective equipment.

---

What changed in the 2024 NIOSH List restructure?

For over a decade, veterinary and human healthcare facilities utilized the 2016 NIOSH List, which organized hazardous drugs into three distinct tables:

• Former Table 1: Antineoplastic (chemotherapy) drugs.
• Former Table 2: Non-antineoplastic hazardous drugs.
• Former Table 3: Drugs that pose primarily reproductive risks.

The 2024 NIOSH List (published December 20, 2024, in 89 FR 104163–104182) completely eliminated the old three-table structure, replacing it with a modernized two-table framework:

2024 NIOSH Hazardous Drug List Restructure
──────────────────────────────────────────────────────────────────────────
New Table Format   Defining Criteria (quoted from the Federal Register)
──────────────────────────────────────────────────────────────────────────
Table 1            Drugs that have Manufacturer's Special Handling
                   Information (MSHI) in the package insert and/or meet
                   the NIOSH definition of a hazardous drug AND are
                   classified by NTP as known human carcinogens or by
                   IARC as Group 1 or Group 2A carcinogens.
                   FR-named examples: mycophenolate mofetil, tacrolimus

Table 2            Drugs that meet the NIOSH definition of a hazardous
                   drug but have neither MSHI nor an NTP/IARC 1 or 2A
                   carcinogen classification — primarily reproductive,
                   developmental, or organ toxins.
                   FR-named examples: sirolimus
──────────────────────────────────────────────────────────────────────────

The examples above are limited to drugs NIOSH names and places by table in the December 2024 Federal Register notice itself. The notice publishes NIOSH's responses to comments and its drug-by-drug determinations — it does not reproduce the full tables. For the complete Table 1 and Table 2 rosters you must consult NIOSH Publication 2025-103 directly. Do not assume a drug is absent from the List because it is not named here.

Critical NIOSH warning: Table 2 is NOT "safe"

A widespread misconception among clinic administrators is assuming that Table 1 represents "dangerous chemotherapy" while Table 2 represents "mild, low-risk medications."

NIOSH explicitly debunked this interpretation in the Federal Register notice:

*"The tables comprising the List are not intended to stratify hazard. Some drugs on Table 2 may be more hazardous than those on Table 1."*

Placement on Table 1 versus Table 2 is dictated strictly by whether the FDA-approved human package insert includes specific manufacturer handling language or an IARC 1/2A carcinogenicity rating—not by the magnitude of biological risk. A reproductive toxin or potent teratogen on Table 2 can cause catastrophic fetal harm upon dermal or inhalation exposure.

Key drug determinations NIOSH published in the 2024 notice

In the December 2024 notice, NIOSH responded to public comments with several drug-specific determinations. These are drugs NIOSH names directly, and several are in daily veterinary use:

• Mycophenolate mofetil: An immunosuppressive drug used in veterinary medicine for immune-mediated hemolytic anemia (IMHA) and skin disease. NIOSH noted that MSHI was added to its prescribing information in 2019 and, in response to comments, moved mycophenolate mofetil to Table 1 — despite it not being an antineoplastic.
• Tacrolimus vs. Sirolimus: A commenter asked NIOSH to move sirolimus to Table 1 precisely because the similar drug tacrolimus (used in veterinary ophthalmology and dermatology) is on Table 1. NIOSH declined, leaving sirolimus on Table 2 — a clean illustration that placement tracks documentation and carcinogen classification, not danger.
• Spironolactone: Two commenters asked for its removal, arguing effects were seen only at high long-term doses. Citing hepatocellular and testicular tumors in rats and effects on estrous cycling and implantation, NIOSH retained spironolactone on the 2024 List, while noting it intends to reevaluate it in a future update.
• Fluconazole: Also proposed for removal. NIOSH retained it, finding the teratogenic effects consistent across species at equivalent doses. It grouped fluconazole with cabergoline, clonazepam, plerixafor, riociguat, and ziprasidone as drugs listed for reproductive and developmental effects.
• Oxytocin and Methylergonovine: Retained on the 2024 List because both "have been observed to pose a hazard to fetuses in the third trimester of pregnancy," though NIOSH intends to reevaluate them.
• Ergonovine Removed: Removed from the 2024 List because it "has never been approved for use in humans by the FDA and therefore does not meet NIOSH's definition as a drug."

Note what that last determination reveals: a drug can leave the List for a regulatory reason rather than a toxicological one. Ergonovine did not become safer.

---

The extralabel reality: Why almost every chemotherapy drug in your building is a human-label product

To understand why human occupational standards govern veterinary oncology, one must examine the veterinary pharmaceutical pipeline.

A comprehensive recomputation of the FDA Animal Drugs @ FDA (Green Book) database (snapshot July 2026, comprising 2,427 approved and withdrawn animal drug applications across 572 distinct active entities) uncovers a striking clinical reality:

FDA Animal Drugs @ FDA (Green Book) Antineoplastic Approvals
──────────────────────────────────────────────────────────────────────────
FDA-Approved Veterinary Antineoplastics (Only 4 Actives in US History!)
──────────────────────────────────────────────────────────────────────────
1. Toceranib phosphate (Palladia) ── Canine mast cell tumors (NADA 141-295, 2009)
2. Rabacfosadine (Tanovea)         ── Canine lymphoma (NADA 141-545, 2021)
3. Verdinexor (Laverdia)           ── Canine lymphoma (NADA 141-614, full
                                      approval 18 December 2025; conditionally
                                      approved January 2021)
4. Tigilanol tiglate (Stelfonta)   ── Canine non-metastatic mast cell (NADA 141-541)
──────────────────────────────────────────────────────────────────────────
Common Cytotoxic Drugs with ZERO FDA Veterinary Approvals (100% Extralabel)
──────────────────────────────────────────────────────────────────────────
• Doxorubicin (Adriamycin)         • Chlorambucil (Leukeran)
• Vincristine & Vinblastine        • Lomustine (CCNU)
• Cyclophosphamide (Cytoxan)       • Carboplatin & Cisplatin
• Mitoxantrone                     • Melphalan (Alkeran)
• Cytarabine (Cytosar-U)           • Hydroxyurea (Hydrea)
──────────────────────────────────────────────────────────────────────────

The AMDUCA connection

Because only four approved small-animal antineoplastic active ingredients exist in the United States, virtually every chemotherapy protocol administered in veterinary oncology (such as the standard CHOP protocol for canine lymphoma treatment or carboplatin for osteosarcoma) relies on human-approved pharmaceuticals used extralabel under AMDUCA.

Two clarifications this counting deserves. First, it counts approvals, not availability — the drugs in the lower half of that box are stocked and used every day in veterinary oncology; they simply have no animal-drug approval. Second, extralabel use is lawful. AMDUCA expressly permits a veterinarian to use a human-approved drug in an animal within a valid veterinarian-client-patient relationship. Nothing here suggests your oncology service is doing something improper. The occupational point is narrower and follows directly:

Consequently:

1. Every package insert, Safety Data Sheet (SDS), and handling warning arriving in your clinic from pharmaceutical distributors was written for human healthcare and pharmacy settings.
2. When OSHA inspects a veterinary hospital handling human cytotoxic agents, it holds the employer to the handling precautions established for those exact chemical entities.

---

Professional and ethical obligations: The AAHA oncology guidelines

Beyond federal OSHA mandates, professional veterinary consensus sets clear standards of care. In the 2016 AAHA Oncology Guidelines for Dogs and Cats (published in the Journal of the American Animal Hospital Association), the American Animal Hospital Association established explicit safe-handling mandates:

"The veterinarian is legally and ethically obligated to educate staff regarding safe handling of chemotherapeutic drugs. Lack of staff communication and training in chemotherapy protocols could lead to an Occupational Safety and Health Administration investigation, fines, and lawsuits."

The AAHA guidelines outline mandatory clinic operational rules:

• Warning Labels: All hazardous drug storage areas, containers, and patient cages must carry high-visibility chemotherapy warning stickers.
• Vial Tracking: All reconstituted or opened injectable hazardous vials must be clearly labeled with the date opened, expiration date, and active concentration.
• Closed-System Transfer Devices (CSTDs): The use of CSTDs (such as PhaSeal, Equashield, or ChemoClave) is strongly recommended to mechanically prohibit the transfer of environmental contaminants and prevent hazardous aerosol release during vial reconstitution and IV spike administration.

---

Actionable 4-step implementation for veterinary clinics on Monday morning

Complying with hazardous drug safety does not require building an expensive cleanroom if your practice does not compound sterile preparations. For general practices and small specialty clinics, compliance is achieved through a structured four-step operational workflow:

                  Monday Morning 4-Step Compliance Workflow
┌────────────────────────────────────────────────────────────────────────────┐
│ STEP 1: Perform a Comprehensive Formulary Hazard Assessment                │
│ • Audit pharmacy inventory against 2024 NIOSH Table 1 & Table 2            │
│ • Flag all cytotoxics, immunosuppressants, hormones, and teratogens        │
└─────────────────────────────────────┬──────────────────────────────────────┘
                                      │
┌─────────────────────────────────────▼──────────────────────────────────────┐
│ STEP 2: Establish Your Written HazCom Program & Active SDS Library         │
│ • Maintain accessible physical binder or 24/7 digital SDS terminal         │
│ • Document mandatory annual staff training in [veterinary assistant files] │
└─────────────────────────────────────┬──────────────────────────────────────┘
                                      │
┌─────────────────────────────────────▼──────────────────────────────────────┐
│ STEP 3: Implement Containment for Tablet Splitting & Compounding           │
│ • Designate a dedicated, low-traffic pill-splitting station                │
│ • NEVER crush cytotoxics on open counters; outsource custom doses to 503A  │
└─────────────────────────────────────┬──────────────────────────────────────┘
                                      │
┌─────────────────────────────────────▼──────────────────────────────────────┐
│ STEP 4: Upgrade PPE Standards & Segregate Hazardous Waste Streams          │
│ • Provide ASTM D6978 chemotherapy gloves & non-permeable disposable gowns  │
│ • Segregate Yellow Trace Chemo vs. Black RCRA Bulk Hazardous Waste         │
└────────────────────────────────────────────────────────────────────────────┘

Step 1: Formulary Hazard Assessment (Audit your shelves)

Walk through your pharmacy and inventory software, cross-referencing your stock against the 2024 NIOSH List. Group the drugs you actually stock into functional handling tiers:

The grouping below is a workflow starting point organized by how a drug is handled and what protection that handling calls for — it is not a reproduction of the NIOSH tables, and inclusion or omission here says nothing about whether a given drug appears on the List. Verify each item in your own formulary against NIOSH Publication 2025-103 and the product's Safety Data Sheet.

Drug Category	Common Veterinary Examples	Primary Biological Hazard	Mandatory Clinic Controls
Antineoplastic Cytotoxics	Doxorubicin, Vincristine, Chlorambucil, Cyclophosphamide, Lomustine, Palladia, Laverdia	Carcinogenicity, Mutagenicity, Bone marrow suppression	ASTM D6978 chemo gloves, CSTD devices, yellow waste bins, no crushing
Immunosuppressive Agents	Mycophenolate mofetil, Cyclosporine (Atopica), Tacrolimus, Azathioprine	Immunosuppression, Teratogenicity, Organ toxicity	Nitrile/chemo gloves, dedicated counting trays, no aerosolization
Endocrine / Hormone Disruptors	Methimazole, Diethylstilbestrol (DES), Finasteride, Trilostane, Progesterone	Teratogenicity, Reproductive toxicity, Fetal harm	Mandatory glove use; pregnant/nursing staff strictly excluded from handling
Prostaglandins & Analogs	Dinoprost (Lutalyse), Misoprostol, Cloprostenol	Severe smooth muscle spasm, Acute abortion, Bronchospasm	Extreme dermal hazard; pregnant personnel prohibited; immediate glove wash

Step 2: Written HazCom program and SDS library

Under 29 CFR 1910.1200, every veterinary employer must maintain:

1. A Written Hazard Communication Plan: Detailing chemical inventories, labeling rules, and protective measures.
2. Accessible Safety Data Sheets (SDSs): An SDS for every hazardous drug must be instantly accessible to all employees on all shifts (either in an indexed yellow binder in the pharmacy or via a bookmarked desktop terminal).
3. Documented Employee Training: Training must occur upon initial hire (logged in the veterinary assistant onboarding file) and whenever a new chemical hazard is introduced.

Step 3: Engineering controls for tablet splitting and compounding

• Dedicated Splitting Station: Never split hazardous pills in general treatment areas, near food prep, or near surgical packs. Establish a designated, cleanable counting and splitting area.
• Dedicated Pill Cutters and Trays: Label pill splitters and counting spatulas with bold colored tape (e.g., "HAZARDOUS DRUGS ONLY—DO NOT USE FOR ANTIBIOTICS"). Wipe cutters with 70% alcohol after every use.
• Outsource Complex Compounding: Never pulverize tablets or empty cytotoxic capsules to make oral liquids on an open countertop. Under FDA Guidance for Industry (GFI) #256, utilize a licensed 503A or 503B veterinary compounding pharmacy equipped with negative-pressure biological safety cabinets.

Step 4: PPE standards and waste stream segregation

Standard thin exam gloves (vinyl or thin latex) do NOT protect against hazardous drugs.

• Chemotherapy Gloves: Staff handling, administering, or cleaning up Table 1/2 drugs must wear powder-free gloves tested to ASTM D6978 (the standard specification for resistance of medical gloves to permeation by chemotherapy drugs). Double-gloving is standard during injectable administration.
• Protective Gowns: Disposable, non-linting, non-permeable gowns with closed fronts and tight cuffs.
• Eye and Respiratory Protection: Use a NIOSH-approved N95 or N100 respirator (not a loose surgical mask) and face shield when handling powders or cleaning spills.

                    Veterinary Waste Stream Segregation
┌────────────────────────────────────────────────────────────────────────────┐
│ 1. YELLOW SHARPS & TRACE WASTE CONTAINER                                   │
│    • Used syringes, needles, empty drug vials, IV tubing, CSTD components  │
│    • Contaminated chemotherapy gloves, gowns, and gauze pads (<3% residue) │
│    • Disposed of via high-temperature incineration                         │
├────────────────────────────────────────────────────────────────────────────┤
│ 2. BLACK RCRA HAZARDOUS CONTAINER (Bulk Waste)                             │
│    • Partially full vials of discarded chemotherapy or hazardous drugs     │
│    • Expired hazardous inventory (see our [expired inventory workflow](/blog/expired-veterinary-inventory-reduction-workflow))    │
│    • Major spill clean-up materials (>3% active drug residue)              │
│    • Managed under federal EPA / state environmental hazardous waste rules │
└────────────────────────────────────────────────────────────────────────────┘

---

Client education and home safety: Sending oral cytotoxics home with pet owners

When sending oral hazardous drugs (such as Palladia, Laverdia, chlorambucil, or cyclophosphamide) home with pet owners, practice liability and patient safety require clear, written discharge protocols:

                  Client Safe-Handling Discharge Checklist
┌────────────────────────────────────────────────────────────────────────────┐
│ • NEVER SPLIT OR CRUSH TABLETS AT HOME                                     │
│   Medications must be administered whole. Never open capsules into food.   │
├────────────────────────────────────────────────────────────────────────────┤
│ • MANDATORY GLOVE USE FOR ADMINISTRATION                                   │
│   Dispense a box of disposable nitrile or chemotherapy gloves with the Rx. │
├────────────────────────────────────────────────────────────────────────────┤
│ • HIGH-RISK INDIVIDUAL EXCLUSION                                           │
│   Pregnant women, nursing mothers, and children must NEVER handle the drug │
│   or clean the pet's waste.                                                │
├────────────────────────────────────────────────────────────────────────────┤
│ • 48-TO-72-HOUR POST-DOSE WASTE PROTOCOL                                  │
│   Active drug metabolites are excreted in urine, feces, saliva, and vomit. │
│   Owners must double-bag feces, wear gloves when cleaning litter boxes,    │
│   and wash contaminated bedding in hot water separately from family laundry│
└────────────────────────────────────────────────────────────────────────────┘

---

Frequently Asked Questions

Is the NIOSH hazardous drug list mandatory for veterinary clinics?

The NIOSH List itself is advisory and informational. However, OSHA actively enforces employee safety standards (29 CFR 1910.1200 and 1910.132) and references the NIOSH List under the General Duty Clause to establish recognized chemical hazards. If an employee is exposed without proper training, SDS access, or certified PPE, OSHA issues citations and penalties.

Do we need a biological safety cabinet to give injectable chemotherapy?

Federal OSHA standards and AAHA oncology guidelines do not strictly require a biological safety cabinet (BSC) for simple administration if the practice does not compound sterile solutions, provided that Closed-System Transfer Devices (CSTDs), double ASTM D6978 chemotherapy gloves, impermeable gowns, eye protection, and specialized spill kits are utilized. However, any reconstituted or drawn-up cytotoxic drug handled without a CSTD or BSC represents an extreme aerosol exposure risk.

Are common non-chemotherapy drugs on the NIOSH list?

Yes — and this is the part most clinics get wrong. Drugs NIOSH names directly in the December 2024 Federal Register notice as being on the 2024 List include mycophenolate mofetil (moved to Table 1), tacrolimus (Table 1), sirolimus (Table 2), spironolactone, fluconazole, oxytocin, and methylergonovine. Several are routine veterinary prescriptions, not oncology drugs. Because the Federal Register notice publishes determinations rather than the complete tables, do not treat any list of examples — including this one — as the full roster. Check your own formulary against NIOSH Publication 2025-103.

Who inspects a veterinary practice for hazardous drug handling?

Federal OSHA (or State OSHA plan compliance officers) conducts unannounced workplace safety inspections. In addition, State Boards of Pharmacy inspect clinics that hold in-house dispensing licenses, and State Veterinary Medical Boards audit standard-of-care compliance. If your clinic is AAHA-accredited, AAHA practice consultants evaluate hazardous drug labeling and storage during site audits.

What do we tell owners who take oral chemotherapy home?

Owners must receive written instructions mandating that pills be administered intact without splitting or crushing. Owners must wear disposable gloves when handling tablets, store medications in child-proof containers away from food, and wear gloves when managing pet urine, feces, or vomit for 48 to 72 hours following each dose.

Where do we get the current NIOSH list, and how often does it change?

The official list is published periodically by NIOSH (CDC). The current edition is the 2024 NIOSH List of Hazardous Drugs in Healthcare Settings (NIOSH Publication 2025-103), finalized in the Federal Register on December 20, 2024. Practices should review their hazardous drug inventory whenever NIOSH publishes an update or when introducing a new pharmaceutical entity into the clinic formulary.

---

Sources

• National Institute for Occupational Safety and Health (NIOSH): Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024; Final Reevaluation Determinations. Federal Register, Vol. 89, No. 245, pages 104163–104182, December 20, 2024. Available at: https://www.govinfo.gov/content/pkg/FR-2024-12-20/html/2024-30456.htm (Accessed August 17, 2026).
• US Occupational Safety and Health Administration (OSHA): Controlling Occupational Exposure to Hazardous Drugs. US Department of Labor. Available at: https://www.osha.gov/hazardous-drugs/controlling-occex (Accessed August 17, 2026).
• US Occupational Safety and Health Administration (OSHA): Standard Interpretation: Hazardous Substances Found in Veterinary Practices. Directorate of Enforcement Programs, May 11, 1993. Available at: https://www.osha.gov/laws-regs/standardinterpretations/1993-05-11 (Accessed August 17, 2026).
• United States Pharmacopeia (USP): General Chapter 800: Hazardous Drugs—Handling in Healthcare Settings. USP-NF. Available at: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare (Accessed August 17, 2026).
• American Animal Hospital Association (AAHA): 2016 AAHA Oncology Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association, 52(4), 181–204. Available at: https://www.aaha.org/wp-content/uploads/globalassets/02-guidelines/oncology/2016_aaha_oncology_guidelines_for_dogs_and_cats.pdf (Accessed August 17, 2026).
• American Veterinary Medical Association (AVMA): SDS 101: Reading and Using Safety Data Sheets. AVMA Practice Management Resources. Available at: https://www.avma.org/resources/practice-management/sds-101-reading-and-using-safety-data-sheets (Accessed August 17, 2026).
• FDA Center for Veterinary Medicine: Animal Drugs @ FDA (Green Book) Approved Animal Drug Products. US Food and Drug Administration. Available at: https://animaldrugsatfda.fda.gov/adafda/views/ (Accessed July 25, 2026 snapshot).